Report Detail
Global Neurological Disorder Drugs Market Insights, Forecast to 2025
- RnM2989707 |
- 08 May, 2019 |
- Global |
- 115 Pages |
- QYResearch |
- Pharma & Healthcare
Several government initiatives across various countries to educate masses about the rise of various diseases and increasing healthcare sector producing new drugs are the prime reasons for growth of neurological disorder drugs market. European Parkinson’s Disease Association, in Europe is actively supporting research and development by campaigning to raise awareness, and providing medication to patients is boosting the overall neurological disorder drugs market. This region is also witnessing rising focus on research and development programs that will help in producing affordable and effective drugs. The countries are collectively spending on developing neurological disorder drugs thus, improving the revenue of the market during the forecast period.
Staggering increase in brain altering disorders such as Alzheimer’s, epilepsy, Parkinson’s, cerebrovascular, and sclerosis are promoting the pharmaceutical firms to tap into the significantly growing neurological disorder drugs market. This will potentially supplement the market growth in the coming years. Rise of several innovative drugs to manage these diseases will swell up the investments in the market. Increasing number of clinical trials are another reason boosting the market. Rise in geriatric population along with patients with strokes, migraines, and headaches leading to cerebrovascular diseases are likely to augment the growth of the market.
The global Neurological Disorder Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Neurological Disorder Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Neurological Disorder Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Neurological Disorder Drugs in these regions.
This research report categorizes the global Neurological Disorder Drugs market by top players/brands, region, type and end user. This report also studies the global Neurological Disorder Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Novartis AG
GlaxoSmithKline plc
Merck & Co.
Bayer AG
AstraZeneca
Boehringer Ingelheim GmbH
Teva Pharmaceutical
Market size by Product
Antipsychotic
Hypnotic & Sedative
Analgesics
Anticoagulants
Others
Market size by End User
Hospital
Clinic
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Neurological Disorder Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Neurological Disorder Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Neurological Disorder Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Neurological Disorder Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Neurological Disorder Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Neurological Disorder Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Neurological Disorder Drugs Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Neurological Disorder Drugs Market Size Growth Rate by Product
- 1.4.2 Antipsychotic
- 1.4.3 Hypnotic & Sedative
- 1.4.4 Analgesics
- 1.4.5 Anticoagulants
- 1.4.6 Others
- 1.5 Market by End User
- 1.5.1 Global Neurological Disorder Drugs Market Size Growth Rate by End User
- 1.5.2 Hospital
- 1.5.3 Clinic
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Neurological Disorder Drugs Market Size
- 2.1.1 Global Neurological Disorder Drugs Revenue 2014-2025
- 2.1.2 Global Neurological Disorder Drugs Sales 2014-2025
- 2.2 Neurological Disorder Drugs Growth Rate by Regions
- 2.2.1 Global Neurological Disorder Drugs Sales by Regions
- 2.2.2 Global Neurological Disorder Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Neurological Disorder Drugs Sales by Manufacturers
- 3.1.1 Neurological Disorder Drugs Sales by Manufacturers
- 3.1.2 Neurological Disorder Drugs Sales Market Share by Manufacturers
- 3.1.3 Global Neurological Disorder Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Neurological Disorder Drugs Revenue by Manufacturers
- 3.2.1 Neurological Disorder Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Neurological Disorder Drugs Revenue Share by Manufacturers (2014-2019)
- 3.3 Neurological Disorder Drugs Price by Manufacturers
- 3.4 Neurological Disorder Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Neurological Disorder Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Neurological Disorder Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Neurological Disorder Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Neurological Disorder Drugs Sales by Product
- 4.2 Global Neurological Disorder Drugs Revenue by Product
- 4.3 Neurological Disorder Drugs Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Neurological Disorder Drugs Breakdown Data by End User
6 North America
- 6.1 North America Neurological Disorder Drugs by Countries
- 6.1.1 North America Neurological Disorder Drugs Sales by Countries
- 6.1.2 North America Neurological Disorder Drugs Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Neurological Disorder Drugs by Product
- 6.3 North America Neurological Disorder Drugs by End User
7 Europe
- 7.1 Europe Neurological Disorder Drugs by Countries
- 7.1.1 Europe Neurological Disorder Drugs Sales by Countries
- 7.1.2 Europe Neurological Disorder Drugs Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Neurological Disorder Drugs by Product
- 7.3 Europe Neurological Disorder Drugs by End User
8 Asia Pacific
- 8.1 Asia Pacific Neurological Disorder Drugs by Countries
- 8.1.1 Asia Pacific Neurological Disorder Drugs Sales by Countries
- 8.1.2 Asia Pacific Neurological Disorder Drugs Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Neurological Disorder Drugs by Product
- 8.3 Asia Pacific Neurological Disorder Drugs by End User
9 Central & South America
- 9.1 Central & South America Neurological Disorder Drugs by Countries
- 9.1.1 Central & South America Neurological Disorder Drugs Sales by Countries
- 9.1.2 Central & South America Neurological Disorder Drugs Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Neurological Disorder Drugs by Product
- 9.3 Central & South America Neurological Disorder Drugs by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Neurological Disorder Drugs by Countries
- 10.1.1 Middle East and Africa Neurological Disorder Drugs Sales by Countries
- 10.1.2 Middle East and Africa Neurological Disorder Drugs Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Neurological Disorder Drugs by Product
- 10.3 Middle East and Africa Neurological Disorder Drugs by End User
11 Company Profiles
- 11.1 Novartis AG
- 11.1.1 Novartis AG Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Novartis AG Neurological Disorder Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Novartis AG Neurological Disorder Drugs Products Offered
- 11.1.5 Novartis AG Recent Development
- 11.2 GlaxoSmithKline plc
- 11.2.1 GlaxoSmithKline plc Company Details
- 11.2.2 Company Business Overview
- 11.2.3 GlaxoSmithKline plc Neurological Disorder Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 GlaxoSmithKline plc Neurological Disorder Drugs Products Offered
- 11.2.5 GlaxoSmithKline plc Recent Development
- 11.3 Merck & Co.
- 11.3.1 Merck & Co. Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Merck & Co. Neurological Disorder Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Merck & Co. Neurological Disorder Drugs Products Offered
- 11.3.5 Merck & Co. Recent Development
- 11.4 Bayer AG
- 11.4.1 Bayer AG Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Bayer AG Neurological Disorder Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Bayer AG Neurological Disorder Drugs Products Offered
- 11.4.5 Bayer AG Recent Development
- 11.5 AstraZeneca
- 11.5.1 AstraZeneca Company Details
- 11.5.2 Company Business Overview
- 11.5.3 AstraZeneca Neurological Disorder Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 AstraZeneca Neurological Disorder Drugs Products Offered
- 11.5.5 AstraZeneca Recent Development
- 11.6 Boehringer Ingelheim GmbH
- 11.6.1 Boehringer Ingelheim GmbH Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Boehringer Ingelheim GmbH Neurological Disorder Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Boehringer Ingelheim GmbH Neurological Disorder Drugs Products Offered
- 11.6.5 Boehringer Ingelheim GmbH Recent Development
- 11.7 Teva Pharmaceutical
- 11.7.1 Teva Pharmaceutical Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Teva Pharmaceutical Neurological Disorder Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Teva Pharmaceutical Neurological Disorder Drugs Products Offered
- 11.7.5 Teva Pharmaceutical Recent Development
12 Future Forecast
- 12.1 Neurological Disorder Drugs Market Forecast by Regions
- 12.1.1 Global Neurological Disorder Drugs Sales Forecast by Regions 2019-2025
- 12.1.2 Global Neurological Disorder Drugs Revenue Forecast by Regions 2019-2025
- 12.2 Neurological Disorder Drugs Market Forecast by Product
- 12.2.1 Global Neurological Disorder Drugs Sales Forecast by Product 2019-2025
- 12.2.2 Global Neurological Disorder Drugs Revenue Forecast by Product 2019-2025
- 12.3 Neurological Disorder Drugs Market Forecast by End User
- 12.4 North America Neurological Disorder Drugs Forecast
- 12.5 Europe Neurological Disorder Drugs Forecast
- 12.6 Asia Pacific Neurological Disorder Drugs Forecast
- 12.7 Central & South America Neurological Disorder Drugs Forecast
- 12.8 Middle East and Africa Neurological Disorder Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Neurological Disorder Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Neurological Disorder Drugs . Industry analysis & Market Report on Neurological Disorder Drugs is a syndicated market report, published as Global Neurological Disorder Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Neurological Disorder Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
